1. Scrip
  2. >>Business
  3. >>Deals

Innate Adds To IO Pipeline With Novo's First-In-Class Anti-C5aR Candidate

 
• By Joseph Haas

Phase I candidate already tested in rheumatoid arthritis could be used to optimize the activity of T cells and NK cells in the tumor microenvironment, either in combination with checkpoint inhibitors or as a solo agent.

Euro currency

Innate Pharma SA will acquire a first-in-class immuno-oncology asset in a deal that could bring new momentum to its cancer pipeline and that also sees the French biotech partnering once again with Novo Nordisk AS.

Novo will get €40m ($45m) up front under the deal, which was announced June 2, most of it in equity. The arrangement will increase the Danish diabetes specialist's stake in Innate from slightly more than 10% to between 14.6% and 15.8%, depending on the latter firm's share price at closing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business